Answers are grounded in this paper and cite their sources.
Transcriptional analysis develops prognostic risk models for lung cancer subtypes, suggesting personalized monitoring can improve outcomes.
Aim: Lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), the two major subtypes of non-small cell lung cancer (NSCLC), possess different immune profiles and potential clinical features. The complex and heterogeneous nature of the tumor microenvironment (TME) demands cell-type–resolved transcriptomic modeling to overcome current limitations in prognostic prediction and therapeutic decision-making. Methods: Through a comprehensive transcriptomic analysis of publicly available single-cell RNAseq datasets, we associated certain immune cell types with prognostic features. We then ranked cell-type-specific marker genes and created prognostic risk models for each lung cancer subtype using a univariate Cox regression approach. We investigated the prognostic potential of our risk score through Kaplan–Meier analysis for overall survival and validated it with external cohorts. Results: We have created disease subtype-specific reduced models with shared genes (such as GZMB, DUSP4, FCER1G, C1QA/B, and IRF7), which also performed comparably well. Conclusions: This study introduces a unique approach to developing prognostic risk scores by comprehensively integrating multiomic data modalities. These models can be utilized in routine clinical monitoring stages in a personalized manner and can help to reduce the burden on healthcare practices.
No takes yet. Share an insight, caveat, or question.
Tuna et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: